2007 Biosimilars Vaccines 
FDA Law Blog: Biosimilars
FEBRUARY 4, 2025
The Tropical Disease PRV program was born the very next year as part of the Food and Drug Administration Amendments Act of 2007 (FDAAA) and expanded in 2014 , which experts heralded as a game-changer for tropical disease therapies.
Pharmaceutical Technology
JULY 23, 2008
Demand for treatment The American Cancer Society estimates that over 12 million new cancer cases were diagnosed worldwide in 2007. “Companies used to be universally protected by patents but there is a pathway to approval opening up for biosimilar legislation. . “You can get vaccines now to prevent cervical cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaShots
APRIL 13, 2023
Its flagship product Humira achieved a $2B global revenue Additionally, Abbott acquired Kos Pharmaceuticals and Guidant's vascular business and launched a new division, Abbott Nutrition International 2007 was a great year for Johnson & Johnson, its consumer health business showed a drastic growth of 48.3% over the previous year.
Pharmaceutical Technology
SEPTEMBER 10, 2008
Secondly, we conduct pre-clinical research and development in the fields of oncology, cardiovascular disorders, anti-influenza vaccines and diabetology. NC: A few projects focusing on influenza, which Biotest was involved with, concluded in 2007. It will most probably lead to a new anti-flu vaccine.
FDA Law Blog: Biosimilars
AUGUST 21, 2023
FDA did, however, try to identify safety issues through the medical literature and (after 2007 when mandatory safety reporting for OTC human drug products marketed without an approved application became effective) through the adverse event reporting system. billion in damages were brought between 1980 and 1986.
pharmaphorum
DECEMBER 2, 2020
“Lipitor…became the biggest-selling prescription medicine ever, earning Pfizer $12 billion a year in 2007, one quarter of its total sales” The areas that Pfizer directed its research into expanded in these years as well.
European Pharmaceutical Review
DECEMBER 23, 2024
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA. EMA/CHMP/ICH/214732/2007. Internet] Vaccines Europe. September 1999, CPMP/ICH/365/96. Eglovitch JS. EU Official Says ICH Q6B Is Outdated And Needs Revision. Internet] Regulatory Focus. cited 2024August]. Available from: [link] 4. Pharmaceutics.
Expert insights. Personalized for you.
52 
Let's personalize your content